Reading the tape
NASDAQ: ANIP
ANI Pharmaceuticals, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
Market Cap
$1.87B
52w High
$99.50
52w Low
$56.71
P/E
21.76
Volume
305.05K
Outstanding Shares
22.75M
Price vs Fundamentals
Why The Stock Is Moving
Fundamentals are supporting the moveModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 13.45%Revenue (TTM): 43.78%FCF (TTM): 169.31%P/FCF: 6th pct
What changed
The stock rose 13.45% over the last year. Revenue grew 43.78% over the trailing twelve months. Operating margin moved from 0.1% to 12.58%. Free cash flow grew 169.31% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum, and the shares are still only around the 6th percentile of their historical P/FCF range.
What would invalidate this read
Operating margin is at 12.58%. Revenue grew 43.78% — this thesis depends on that trajectory holding. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Company profile
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.
CEONikhil Lalwani
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees897
IPO dateMay 5, 2000
Valuation
Forward P/E—
EV/EBITDA7.83
Enterprise value$1.62B
Stock splits
Jul 18, 2013↓ Reverse
Every 6 shares became 1
Jun 4, 2012↓ Reverse
Every 6 shares became 1
Jun 3, 2002↓ Reverse
Every 10 shares became 1
Profitability & growth
Revenue growth29.64%
Gross margin69.08%▼13.94%vs FY2024
Operating margin12.58%▲9573.80%vs FY2024
ROE14.49%▲435.19%vs FY2024
Analyst consensus
RatingBuy
Target price$124.00▲50.63%
7
Buy
3
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 8, 2026
Q2 FY26 · EPS est $1.28 · Revenue est $207.63M
View